Tang Zhongben, Lin Feng, Xiao Jiarong, Du Xiaojun, Zhang Jian, Li Sini, Tang Gongshun, Chen Chen, Li Jian
Department of Thoracic, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Department of Thoracic, West China Hospital of Sichuan University, Chengdu, China.
Front Oncol. 2021 Mar 18;11:605658. doi: 10.3389/fonc.2021.605658. eCollection 2021.
Primary pulmonary adenoid cystic carcinomas are salivary tumors that are low-grade malignant and prone to recurrence and metastasis. Surgery is currently the main treatment, but there is no standard with regard to postoperative adjuvant therapy. Adenoid cystic carcinoma is more sensitive to radiotherapy and patients benefit less from chemotherapy, but few studies have focused on targeted therapy, and their conclusions are inconsistent. With respect to primary pulmonary adenoid cystic carcinoma, large-scale studies cannot be conducted due to its low incidence, and studies on the targeted therapy of it are very scarce. A few case reports indicate that targeted therapy can be effective however, suggesting that it may be a good option. The current report is the first on the occurrence of human epidermal growth factor receptor 2 amplification in pulmonary adenoid cystic carcinoma. The patient was treated with pyrotinib for 6 months and achieved stable disease.
原发性肺腺样囊性癌是涎腺肿瘤，为低级别恶性肿瘤，易于复发和转移。手术是目前的主要治疗方法，但术后辅助治疗尚无标准。腺样囊性癌对放疗更敏感，患者从化疗中获益较少，但很少有研究聚焦于靶向治疗，且结论不一致。对于原发性肺腺样囊性癌，由于其发病率低，无法进行大规模研究，对其靶向治疗的研究非常稀少。然而，一些病例报告表明靶向治疗可能有效，提示其可能是一个不错的选择。本报告是首例关于肺腺样囊性癌中人类表皮生长因子受体2扩增的报道。该患者接受吡咯替尼治疗6个月，病情稳定。
